Journal of Obstetrics and Gynaecology Research最新文献_第10页

Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017 日本妇产科学会妇科肿瘤委员会年度报告：2022年年度患者报告和2017年年度治疗报告

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70124

Hiroaki Kajiyama, Satoshi Tamauchi, Fumiaki Takahashi, Toyomi Satoh, Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology

Aim

To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2022 and the Annual Treatment Report for 2017, on the outcomes of patients who started treatment in 2017.

Methods

The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2022 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2017 was analyzed by using the Kaplan–Meier, log–rank, and Wilcoxson tests.

Results

Treatment was initiated in 2022 for 8039 patients with cervical cancer, 14 518 with endometrial cancer, 8524 with ovarian, tubal, and peritoneal cancer, 2360 with ovarian borderline tumors, and with the others (270 vulvar cancer, 179 vaginal cancer, 539 uterine sarcoma, 48 uterine adenosarcoma, 158 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2017 were as follows. For cervical cancer, the rates were 93.0%, 76.1%, 59.5%, and 28.3% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.9%, 88.8%, 72.7%, and 28.9% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 91.7%, 76.6%, 54.4%, and 45.2% for Stages I, II, III, and IV, respectively.

Conclusion

The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

为了提供包括日本妇科恶性肿瘤趋势在内的信息，我们特此发布《2022年年度患者报告》和《2017年年度治疗报告》，介绍2017年开始治疗的患者的结果。方法日本妇产科学会每年进行肿瘤登记，收集来自各参与机构的妇科恶性肿瘤信息。回顾性分析我院2022年开始妇科恶性肿瘤治疗的患者资料。2017年开始接受宫颈癌、子宫内膜癌和卵巢癌治疗的患者的生存期通过Kaplan-Meier、log-rank和Wilcoxson检验进行分析。结果2022年开始治疗宫颈癌8039例，子宫内膜癌14518例，卵巢癌、输卵管癌和腹膜癌8524例，卵巢交界性肿瘤2360例，其他（外阴癌270例，阴道癌179例，子宫肉瘤539例，子宫腺肉瘤48例，滋养细胞疾病158例）。这些临床病理信息被总结为患者年度报告。2017年开始治疗的患者5年生存率如下：至于子宫颈癌，第一、二、三、四期的发病率分别为93.0%、76.1%、59.5%和28.3%。对于子宫内膜癌，I期、II期、III期和IV期的发生率分别为94.9%、88.8%、72.7%和28.9%。对于卵巢癌，I期、II期、III期和IV期的发病率分别为91.7%、76.6%、54.4%和45.2%。结论年度肿瘤报告是了解日本妇科恶性肿瘤发展趋势的重要调查资料。

{"title":"Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017","authors":"Hiroaki Kajiyama, Satoshi Tamauchi, Fumiaki Takahashi, Toyomi Satoh, Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology","doi":"10.1111/jog.70124","DOIUrl":"https://doi.org/10.1111/jog.70124","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2022 and the Annual Treatment Report for 2017, on the outcomes of patients who started treatment in 2017.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2022 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2017 was analyzed by using the Kaplan–Meier, log–rank, and Wilcoxson tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Treatment was initiated in 2022 for 8039 patients with cervical cancer, 14 518 with endometrial cancer, 8524 with ovarian, tubal, and peritoneal cancer, 2360 with ovarian borderline tumors, and with the others (270 vulvar cancer, 179 vaginal cancer, 539 uterine sarcoma, 48 uterine adenosarcoma, 158 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2017 were as follows. For cervical cancer, the rates were 93.0%, 76.1%, 59.5%, and 28.3% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.9%, 88.8%, 72.7%, and 28.9% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 91.7%, 76.6%, 54.4%, and 45.2% for Stages I, II, III, and IV, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence, Risk Factors, and Outcomes of Complete Uterine Rupture: A 10-Year Single-Center Retrospective Study 完全性子宫破裂的发生率、危险因素和结局：一项10年单中心回顾性研究

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70122

Zhexia Hu, Hong Zhang, Yun Rong, Biyun Luo, Mengjia Wang, Xueling Zhang, Tianhong Gao

Objective

This study aims to analyze the incidence, risk factors, clinical presentations, and maternal-perinatal outcomes of complete uterine rupture at a major tertiary hospital in China over a decade.

Methods

We conducted a single-center retrospective cohort study of all women who delivered at our hospital, from March 2012 to February 2022. Cases of complete uterine rupture, defined as a full-thickness tear of the uterine wall confirmed intraoperatively, were identified. Data on demographics, obstetric history, clinical manifestations, management, and outcomes were extracted and analyzed using descriptive statistics.

Results

Out of 232,563 total deliveries, 38 cases of complete uterine rupture were confirmed, yielding an incidence of 0.016% (1.6 per 10,000 deliveries). The median maternal age was 31 years (range, 23–38), and the median gestational age at rupture was 36⁺⁴ weeks (range, 13⁺⁶–40⁺⁶). A prior uterine scar was the predominant risk factor, present in 32 cases (84.2%), primarily from previous cesarean sections. Rupture occurred in unscarred uteri in 6 cases (15.8%). Clinical presentation was highly variable: acute abdominal pain was the most common symptom (n = 20, 52.6%), followed by vaginal bleeding (n = 8, 21.1%) and fetal heart rate abnormalities (n = 10, 26.3%). Notably, 8 patients (21.1%) were asymptomatic, with the rupture discovered incidentally during elective cesarean section. Maternal morbidity was significant, although all mothers survived; however, the perinatal mortality rate was high at 27.5% (11 of 40 fetuses/newborns). Thirty-seven (97.4%) patients underwent uterine repair, and one (2.6%) required a hysterectomy.

Conclusion

A prior uterine scar is the leading risk factor for complete uterine rupture. However, the heterogeneous clinical presentation, including a significant proportion of asymptomatic cases, poses a major diagnostic challenge. A high index of suspicion is crucial for timely intervention to mitigate adverse maternal and perinatal outcomes.

目的分析国内某大型三级医院近十年来完全性子宫破裂的发生率、危险因素、临床表现及母婴结局。方法对2012年3月至2022年2月在我院分娩的所有妇女进行单中心回顾性队列研究。病例完全子宫破裂，定义为全层撕裂子宫壁确认术中，被确定。提取人口统计学、产科史、临床表现、管理和结局的数据，并使用描述性统计进行分析。结果232,563例分娩中，子宫完全破裂38例，发生率为0.016%（1.6 / 10000例）。产妇的中位年龄为31岁（范围23-38），破裂时的中位胎龄为36+4周（范围13+6 - 40+6）。既往子宫瘢痕是主要危险因素，32例（84.2%），主要来自既往剖宫产手术。无瘢痕子宫破裂6例（15.8%）。临床表现差异很大：急性腹痛是最常见的症状（n = 20, 52.6%），其次是阴道出血（n = 8, 21.1%）和胎儿心率异常（n = 10, 26.3%）。值得注意的是，8例（21.1%）患者无症状，破裂是在择期剖宫产术中偶然发现的。尽管所有母亲都存活了下来，但产妇发病率很高；然而，围产期死亡率高达27.5%（40个胎儿/新生儿中有11个）。37例（97.4%）患者行子宫修复术，1例（2.6%）患者行子宫切除术。结论子宫瘢痕是导致子宫完全破裂的主要危险因素。然而，异质性的临床表现，包括相当大比例的无症状病例，构成了一个主要的诊断挑战。高怀疑指数对于及时干预以减轻不利的孕产妇和围产期结局至关重要。

{"title":"Incidence, Risk Factors, and Outcomes of Complete Uterine Rupture: A 10-Year Single-Center Retrospective Study","authors":"Zhexia Hu, Hong Zhang, Yun Rong, Biyun Luo, Mengjia Wang, Xueling Zhang, Tianhong Gao","doi":"10.1111/jog.70122","DOIUrl":"https://doi.org/10.1111/jog.70122","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aims to analyze the incidence, risk factors, clinical presentations, and maternal-perinatal outcomes of complete uterine rupture at a major tertiary hospital in China over a decade.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a single-center retrospective cohort study of all women who delivered at our hospital, from March 2012 to February 2022. Cases of complete uterine rupture, defined as a full-thickness tear of the uterine wall confirmed intraoperatively, were identified. Data on demographics, obstetric history, clinical manifestations, management, and outcomes were extracted and analyzed using descriptive statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 232,563 total deliveries, 38 cases of complete uterine rupture were confirmed, yielding an incidence of 0.016% (1.6 per 10,000 deliveries). The median maternal age was 31 years (range, 23–38), and the median gestational age at rupture was 36<sup>+4</sup> weeks (range, 13<sup>+6</sup>–40<sup>+6</sup>). A prior uterine scar was the predominant risk factor, present in 32 cases (84.2%), primarily from previous cesarean sections. Rupture occurred in unscarred uteri in 6 cases (15.8%). Clinical presentation was highly variable: acute abdominal pain was the most common symptom (<i>n</i> = 20, 52.6%), followed by vaginal bleeding (<i>n</i> = 8, 21.1%) and fetal heart rate abnormalities (<i>n</i> = 10, 26.3%). Notably, 8 patients (21.1%) were asymptomatic, with the rupture discovered incidentally during elective cesarean section. Maternal morbidity was significant, although all mothers survived; however, the perinatal mortality rate was high at 27.5% (11 of 40 fetuses/newborns). Thirty-seven (97.4%) patients underwent uterine repair, and one (2.6%) required a hysterectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A prior uterine scar is the leading risk factor for complete uterine rupture. However, the heterogeneous clinical presentation, including a significant proportion of asymptomatic cases, poses a major diagnostic challenge. A high index of suspicion is crucial for timely intervention to mitigate adverse maternal and perinatal outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Concurrent Chemoradiotherapy as First-Line Treatment for Stage IVB Cervical Cancer: A Single-Center Retrospective Observational Study 同步放化疗作为IVB期宫颈癌一线治疗的疗效和安全性：一项单中心回顾性观察研究

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70119

Yumi Ishidera, Takayoshi Iijima, Masahiro Aichi, Yuki Ogawara, Yuichi Imai, Madoka Sugiura, Masaharu Hata, Etsuko Miyagi, Taichi Mizushima

Aim

To evaluate the efficacy and safety of concurrent chemoradiotherapy prior to systemic chemotherapy in patients with stage IVB cervical cancer.

Methods

This retrospective observational study included 40 patients diagnosed with stage IVB cervical cancer who received concurrent chemoradiotherapy as first-line therapy at the Yokohama City University Hospital between 2007 and 2021. The evaluated outcomes included concurrent chemoradiotherapy response rate, chemotherapy initiation rate, adverse events, and overall survival.

Results

The disease control rate of concurrent chemoradiotherapy was 72.5%, with no significant differences across the subgroups defined by the number of metastatic sites, presence of out-of-field lesions, parenchymal involvement, or histological subtype. Systemic chemotherapy was initiated in 89% of the patients, with a median interval of 39 days after concurrent chemoradiotherapy completion, except in one patient (3.6%) due to disease progression. Including recurrent cases, 91% of patients ultimately received systemic chemotherapy. Grade 3 or higher toxicity that significantly delayed chemotherapy initiation occurred in only one patient (3.6%). The median overall survival was 23 months, with no significant differences based on lesion distribution, parenchymal involvement, histological subtype, or metastatic burden.

Conclusions

Concurrent chemoradiotherapy may be a feasible first-line treatment option for stage IVB cervical cancer with manageable toxicity, acceptable disease control, and the potential to allow a timely transition to systemic chemotherapy.

目的评价IVB期宫颈癌患者全身化疗前同步放化疗的疗效和安全性。方法本回顾性观察研究纳入了40例诊断为IVB期宫颈癌的患者，这些患者于2007年至2021年间在横滨市立大学医院接受同步放化疗作为一线治疗。评估的结果包括同步放化疗反应率、化疗起始率、不良事件和总生存率。结果同步放化疗的疾病控制率为72.5%，在转移部位数量、有无场外病变、实质受损伤或组织学亚型的亚组之间无显著差异。89%的患者开始了全身化疗，在同步放化疗完成后的中位间隔为39天，除了一名患者（3.6%）由于疾病进展。包括复发病例在内，91%的患者最终接受了全身化疗。3级或更高毒性显著延迟化疗起始仅发生在1例患者中（3.6%）。中位总生存期为23个月，基于病变分布、实质受累、组织学亚型或转移负担无显著差异。结论同步放化疗可能是IVB期宫颈癌的一种可行的一线治疗选择，其毒性可控，疾病控制可接受，并有可能及时过渡到全身化疗。

{"title":"Efficacy and Safety of Concurrent Chemoradiotherapy as First-Line Treatment for Stage IVB Cervical Cancer: A Single-Center Retrospective Observational Study","authors":"Yumi Ishidera, Takayoshi Iijima, Masahiro Aichi, Yuki Ogawara, Yuichi Imai, Madoka Sugiura, Masaharu Hata, Etsuko Miyagi, Taichi Mizushima","doi":"10.1111/jog.70119","DOIUrl":"https://doi.org/10.1111/jog.70119","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of concurrent chemoradiotherapy prior to systemic chemotherapy in patients with stage IVB cervical cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective observational study included 40 patients diagnosed with stage IVB cervical cancer who received concurrent chemoradiotherapy as first-line therapy at the Yokohama City University Hospital between 2007 and 2021. The evaluated outcomes included concurrent chemoradiotherapy response rate, chemotherapy initiation rate, adverse events, and overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The disease control rate of concurrent chemoradiotherapy was 72.5%, with no significant differences across the subgroups defined by the number of metastatic sites, presence of out-of-field lesions, parenchymal involvement, or histological subtype. Systemic chemotherapy was initiated in 89% of the patients, with a median interval of 39 days after concurrent chemoradiotherapy completion, except in one patient (3.6%) due to disease progression. Including recurrent cases, 91% of patients ultimately received systemic chemotherapy. Grade 3 or higher toxicity that significantly delayed chemotherapy initiation occurred in only one patient (3.6%). The median overall survival was 23 months, with no significant differences based on lesion distribution, parenchymal involvement, histological subtype, or metastatic burden.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Concurrent chemoradiotherapy may be a feasible first-line treatment option for stage IVB cervical cancer with manageable toxicity, acceptable disease control, and the potential to allow a timely transition to systemic chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/jog.70119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancytopenia in the Third Trimester of Pregnancy: A Case of Concurrent Folate and Zinc Deficiencies due to Unbalanced Dietary Habits 妊娠晚期全血细胞减少症：由于饮食习惯不平衡导致的叶酸和锌缺乏症

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70114

Minori Tanabe, Yusuke Kurokawa, Megumi Muto, Maki Yamaguchi, Toshiyuki Yoshizato, Koji Nagafuji, Naotake Tsuda

A 25-year-old pregnant woman (gravida 2, para 1) presented with progressive anemia unresponsive to iron supplementation, ultimately developing pancytopenia at 37 weeks of gestation. Despite adequate caloric intake, her diet consisted primarily of ultra-processed and frozen foods. Laboratory findings showed hemoglobin of 5.5 g/dL, mean corpuscular volume of 102.9 fL, and elevated lactate dehydrogenase. Her serum folate, vitamin B₁₂, and zinc levels were 1.3 ng/mL, 131 pg/mL, and 57 μg/dL, respectively. A healthy infant was delivered via cesarean section at 38 weeks, and the mother's pancytopenia improved with supplementation. To our knowledge, few reports have described concurrent folate- and zinc-deficiency–associated pancytopenia during pregnancy without significant weight loss or overt dietary restriction, particularly in the context of a diet high in ultra-processed foods but with sufficient caloric intake. This case highlights the risks of poor micronutrient intake despite adequate macronutrient consumption and underscores the importance of nutritional monitoring during pregnancy.

一名25岁的孕妇（妊娠2期，第1段）出现进行性贫血，对补铁无反应，最终在妊娠37周发生全血细胞减少症。尽管摄入了足够的热量，但她的饮食主要是超加工食品和冷冻食品。实验室结果显示血红蛋白5.5 g/dL，平均红细胞体积102.9 fL，乳酸脱氢酶升高。她的血清叶酸、维生素B12和锌水平分别为1.3 ng/mL、131 pg/mL和57 μg/dL。一个健康的婴儿在38周时通过剖宫产分娩，母亲的全血细胞减少症在补充后得到改善。据我们所知，很少有报告描述孕期叶酸和锌缺乏症相关的全血细胞减少症，而没有明显的体重减轻或明显的饮食限制，特别是在饮食中含有大量超加工食品但热量摄入充足的情况下。该病例突出了尽管大量营养素摄入充足，但微量营养素摄入不足的风险，并强调了怀孕期间营养监测的重要性。

{"title":"Pancytopenia in the Third Trimester of Pregnancy: A Case of Concurrent Folate and Zinc Deficiencies due to Unbalanced Dietary Habits","authors":"Minori Tanabe, Yusuke Kurokawa, Megumi Muto, Maki Yamaguchi, Toshiyuki Yoshizato, Koji Nagafuji, Naotake Tsuda","doi":"10.1111/jog.70114","DOIUrl":"https://doi.org/10.1111/jog.70114","url":null,"abstract":"<div>\u0000 \u0000 <p>A 25-year-old pregnant woman (gravida 2, para 1) presented with progressive anemia unresponsive to iron supplementation, ultimately developing pancytopenia at 37 weeks of gestation. Despite adequate caloric intake, her diet consisted primarily of ultra-processed and frozen foods. Laboratory findings showed hemoglobin of 5.5 g/dL, mean corpuscular volume of 102.9 fL, and elevated lactate dehydrogenase. Her serum folate, vitamin B<sub>12</sub>, and zinc levels were 1.3 ng/mL, 131 pg/mL, and 57 μg/dL, respectively. A healthy infant was delivered via cesarean section at 38 weeks, and the mother's pancytopenia improved with supplementation. To our knowledge, few reports have described concurrent folate- and zinc-deficiency–associated pancytopenia during pregnancy without significant weight loss or overt dietary restriction, particularly in the context of a diet high in ultra-processed foods but with sufficient caloric intake. This case highlights the risks of poor micronutrient intake despite adequate macronutrient consumption and underscores the importance of nutritional monitoring during pregnancy.</p>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to “Predicting Fetal Distress in Growth-Restricted Fetuses: The Role of Umbilical Vein Diameter” 致“预测生长受限胎儿的胎儿窘迫：脐静脉直径的作用”的信

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70126

Hiroyuki Tokue, Yoshito Tsushima

引用次数: 0

Rare Intronic Variants Altering Splicing Cause Lynch Syndrome: Two Case Reports 改变剪接的罕见内含子变异导致Lynch综合征：两例报告

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70117

Yumi Takimoto, Hiroshi Tsubamoto, Tomokazu Wakatsuki, Riyo Yoshii, Gou Yamamoto, Hideaki Sawai, Ikuo Matsuda, Naohiro Tomita, Seiji Mabuchi, Kiwamu Akagi

Lynch syndrome (LS) is an autosomal-dominant hereditary cancer syndrome caused by defective mismatch repair (MMR) genes. This report presents two cases of LS with rare intronic variants in MLH1 and MSH2 that affect splicing, leading to diagnostic challenges and implications for management. The first case involves a 50-year-old woman with a history of colorectal and endometrial cancers, identified with a MSH2 c.2458+976A>G variant, resulting in pseudo-exon inclusion. The second case describes a 70-year-old woman with synchronous endometrial and cecal cancers, carrying an MLH1 c.545+4_545+5del variant, which caused exon 6 skipping. Both cases have strong familial and/or medical histories of LS-related cancers, but no pathogenic variant has been detected by conventional genetic testing. In these cases, RNA sequencing played a crucial role in establishing a definitive diagnosis. These findings highlight the need for genetic testing beyond conventional exon-focused sequencing to ensure accurate diagnosis and management.

Lynch综合征（LS）是一种常染色体显性遗传性癌症综合征，由缺陷错配修复（MMR）基因引起。本报告报告了两例LS患者，其MLH1和MSH2中罕见的内含子变异影响剪接，导致诊断挑战和管理意义。第一例患者为一名有结直肠癌和子宫内膜癌病史的50岁女性，被鉴定为MSH2 c.2458+976A>；G变异，导致假外显子包含。第二个病例描述了一名患有同步子宫内膜癌和盲肠癌的70岁女性，携带MLH1 c.545+4_545+5del变异，导致外显子6跳变。两例患者均有强烈的ls相关癌症家族史和/或病史，但常规基因检测未发现致病性变异。在这些病例中，RNA测序在确定明确的诊断中起着至关重要的作用。这些发现强调了基因检测需要超越传统的外显子聚焦测序，以确保准确的诊断和管理。

{"title":"Rare Intronic Variants Altering Splicing Cause Lynch Syndrome: Two Case Reports","authors":"Yumi Takimoto, Hiroshi Tsubamoto, Tomokazu Wakatsuki, Riyo Yoshii, Gou Yamamoto, Hideaki Sawai, Ikuo Matsuda, Naohiro Tomita, Seiji Mabuchi, Kiwamu Akagi","doi":"10.1111/jog.70117","DOIUrl":"https://doi.org/10.1111/jog.70117","url":null,"abstract":"<div>\u0000 \u0000 <p>Lynch syndrome (LS) is an autosomal-dominant hereditary cancer syndrome caused by defective mismatch repair (MMR) genes. This report presents two cases of LS with rare intronic variants in MLH1 and MSH2 that affect splicing, leading to diagnostic challenges and implications for management. The first case involves a 50-year-old woman with a history of colorectal and endometrial cancers, identified with a MSH2 c.2458+976A>G variant, resulting in pseudo-exon inclusion. The second case describes a 70-year-old woman with synchronous endometrial and cecal cancers, carrying an MLH1 c.545+4_545+5del variant, which caused exon 6 skipping. Both cases have strong familial and/or medical histories of LS-related cancers, but no pathogenic variant has been detected by conventional genetic testing. In these cases, RNA sequencing played a crucial role in establishing a definitive diagnosis. These findings highlight the need for genetic testing beyond conventional exon-focused sequencing to ensure accurate diagnosis and management.</p>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Texture Analysis of Uterine-Derived T2-Weighted Imaging in Patients With Primary Dysmenorrhea Across Different Menstrual Phases 不同月经期原发性痛经患者子宫源性t2加权成像的纹理分析

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70123

Ke Wang, Huiping Liu, Huiyan Gan, Meiling Shang, Jing Yang, Tongtong Fan, Jixin Liu, Yihao Peng, Ming Zhang, Wanghuan Dun

Purpose

Primary dysmenorrhea (PDM) affects 45%–95% of menstruating women. However, the mechanism of PDM is still unclear; abnormal uterine structure may be one of the causes of PDM. But the subtle structural changes of the uterus during the menstrual phase cannot be seen by the naked eye. Here, we perform magnetic resonance imaging (MRI) texture analysis to precisely quantify the subtle changes of the uterus in patients with PDM.

Methods

Fifty-one patients with PDM and 49 healthy controls (HCs) underwent pelvic MRI during the menstrual and periovulatory phases and were included in this study. Sagittal T2-weighted images were uploaded into 3D slicer software for textural analysis of uterine structures (myometrium, junctional zone, endometrium). SPSS software was used for all statistical analyses of demographics and texture parameters.

Results

We found a phase × group interaction in small-zone emphasis (SZE) (p = 0.006, $� � � �_{η}^{�} � � �$ = 0.144) and zone percentage (ZP) (p = 0.007, $� � � �_{η}^{�} � � �$ = 0.148). The changes of textural characteristics of the myometrium were smaller in patients with PDM from preovulatory to menstrual phase compared with HCs. Additionally, we found the changes in SZE and ZP in the myometrium across the menstrual cycle were positively correlated with pain intensity in patients with PDM during menstrual phase.

Conclusions

Our study demonstrates that patients with PDM exhibit persistent subtle uterine abnormalities across the menstrual cycle, suggesting that PDM represents a continuous pathophysiological state rather than a transient menstrual-phase disorder. We propose texture analysis may provide a novel objective method for the early detection and prevention of PDM.

目的原发性痛经（PDM）影响45%–95% of menstruating women. However, the mechanism of PDM is still unclear; abnormal uterine structure may be one of the causes of PDM. But the subtle structural changes of the uterus during the menstrual phase cannot be seen by the naked eye. Here, we perform magnetic resonance imaging (MRI) texture analysis to precisely quantify the subtle changes of the uterus in patients with PDM. Methods Fifty-one patients with PDM and 49 healthy controls (HCs) underwent pelvic MRI during the menstrual and periovulatory phases and were included in this study. Sagittal T2-weighted images were uploaded into 3D slicer software for textural analysis of uterine structures (myometrium, junctional zone, endometrium). SPSS software was used for all statistical analyses of demographics and texture parameters. Results We found a phase × group interaction in small-zone emphasis (SZE) (p = 0.006, η p 2 $$ {eta}_p^2 $$ = 0.144) and zone percentage (ZP) (p = 0.007, η p 2 $$ {eta}_p^2 $$ = 0.148). The changes of textural characteristics of the myometrium were smaller in patients with PDM from preovulatory to menstrual phase compared with HCs. Additionally, we found the changes in SZE and ZP in the myometrium across the menstrual cycle were positively correlated with pain intensity in patients with PDM during menstrual phase. Conclusions Our study demonstrates that patients with PDM exhibit persistent subtle uterine abnormalities across the menstrual cycle, suggesting that PDM represents a continuous pathophysiological state rather than a transient menstrual-phase disorder. We propose texture analysis may provide a novel objective method for the early detection and prevention of PDM.

{"title":"Texture Analysis of Uterine-Derived T2-Weighted Imaging in Patients With Primary Dysmenorrhea Across Different Menstrual Phases","authors":"Ke Wang, Huiping Liu, Huiyan Gan, Meiling Shang, Jing Yang, Tongtong Fan, Jixin Liu, Yihao Peng, Ming Zhang, Wanghuan Dun","doi":"10.1111/jog.70123","DOIUrl":"https://doi.org/10.1111/jog.70123","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Primary dysmenorrhea (PDM) affects 45%–95% of menstruating women. However, the mechanism of PDM is still unclear; abnormal uterine structure may be one of the causes of PDM. But the subtle structural changes of the uterus during the menstrual phase cannot be seen by the naked eye. Here, we perform magnetic resonance imaging (MRI) texture analysis to precisely quantify the subtle changes of the uterus in patients with PDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-one patients with PDM and 49 healthy controls (HCs) underwent pelvic MRI during the menstrual and periovulatory phases and were included in this study. Sagittal T2-weighted images were uploaded into 3D slicer software for textural analysis of uterine structures (myometrium, junctional zone, endometrium). SPSS software was used for all statistical analyses of demographics and texture parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found a phase × group interaction in small-zone emphasis (SZE) (<i>p</i> = 0.006, <span></span><math>\u0000 <semantics>\u0000 <mrow>\u0000 <msubsup>\u0000 <mi>η</mi>\u0000 <mi>p</mi>\u0000 <mn>2</mn>\u0000 </msubsup>\u0000 </mrow>\u0000 <annotation>$$ {eta}_p^2 $$</annotation>\u0000 </semantics></math> = 0.144) and zone percentage (ZP) (<i>p</i> = 0.007, <span></span><math>\u0000 <semantics>\u0000 <mrow>\u0000 <msubsup>\u0000 <mi>η</mi>\u0000 <mi>p</mi>\u0000 <mn>2</mn>\u0000 </msubsup>\u0000 </mrow>\u0000 <annotation>$$ {eta}_p^2 $$</annotation>\u0000 </semantics></math> = 0.148). The changes of textural characteristics of the myometrium were smaller in patients with PDM from preovulatory to menstrual phase compared with HCs. Additionally, we found the changes in SZE and ZP in the myometrium across the menstrual cycle were positively correlated with pain intensity in patients with PDM during menstrual phase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study demonstrates that patients with PDM exhibit persistent subtle uterine abnormalities across the menstrual cycle, suggesting that PDM represents a continuous pathophysiological state rather than a transient menstrual-phase disorder. We propose texture analysis may provide a novel objective method for the early detection and prevention of PDM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Valproic Acid Use in Pregnant Women: A Systematic Review and Meta-Analysis 孕妇使用丙戊酸的安全性：一项系统综述和荟萃分析

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70121

Xinying Yang, Yiqi Sun, Zixin Hua, Taoran Li, Xingang Li, Pengqiang Du

Objective

To evaluate valproic acid (VPA) safety in pregnancy versus other antiepileptic drugs (AEDs), focusing on fetal malformation risks.

Methods

A literature search was conducted across PUBMED, MEDLINE, EMBASE, and Web of Science databases. Two researchers independently screened studies, extracted data, assessed quality, and analyzed VPA safety.

Results

This meta-analysis of 25 safety studies showed that compared with other AEDs, VPA's teratogenic risks were as follows: combined major congenital malformations (RR = 2.36, 95% CI: 2.17–2.56), neural tube defects (RR = 6.54, 95% CI: 4.51–9.47), congenital heart defects (RR = 2.53, 95% CI: 2.16–2.96), cleft lip and/or palate (RR = 4.31, 95% CI: 3.06–6.08), genitourinary anomalies (RR = 3.32, 95% CI: 2.67–4.14), and musculoskeletal anomalies (RR = 2.88, 95% CI: 1.98–4.19). Additional analyses stratified by calendar era yielded consistent results, with the corresponding RR values for the above malformations being 2.43 (95% CI: 2.13–2.77), 6.64 (95% CI: 4.50–9.79), 2.64 (95% CI: 2.14–3.26), 4.27 (95% CI: 2.98–6.12), 3.45 (95% CI: 2.76–4.31), and 2.99 (95% CI: 2.00–4.46), indicating a higher risk of multiple malformations with VPA.

Conclusion

VPA monotherapy significantly increases teratogenic risk, especially for neural tube defects and cleft lip/palate. Newer AEDs with lower risk profiles are preferred for epilepsy treatment during pregnancy. If VPA use is unavoidable, low doses and blood concentration monitoring are recommended to mitigate risk.

目的评价丙戊酸（VPA）与其他抗癫痫药物（aed）在妊娠期的安全性，重点关注胎儿畸形风险。方法通过PUBMED、MEDLINE、EMBASE和Web of Science数据库进行文献检索。两名研究人员独立筛选研究，提取数据，评估质量，并分析VPA安全性。结果25项安全性研究的荟萃分析显示，与其他aed相比，VPA的致畸风险如下：合并重大先天性畸形（RR = 2.36, 95% CI: 2.17-2.56）、神经管缺陷（RR = 6.54, 95% CI: 4.51-9.47）、先天性心脏缺陷（RR = 2.53, 95% CI: 2.16-2.96）、唇裂和/或腭裂（RR = 4.31, 95% CI: 3.06-6.08）、泌尿生殖系统异常（RR = 3.32, 95% CI: 2.67-4.14）和肌肉骨骼异常（RR = 2.88, 95% CI: 2.88）。1.98 - -4.19)。按日历年代分层的其他分析得出了一致的结果，上述畸形的相应RR值为2.43 （95% CI: 2.13-2.77）、6.64 （95% CI: 4.50-9.79）、2.64 （95% CI: 2.14-3.26）、4.27 （95% CI: 2.98-6.12）、3.45 （95% CI: 2.76-4.31）和2.99 (95% CI: 2.00-4.46)，表明VPA合并多发性畸形的风险较高。结论VPA单药治疗明显增加了神经管缺损和唇腭裂的致畸风险。较低风险的新型抗癫痫药是妊娠期癫痫治疗的首选。如果使用VPA是不可避免的，建议使用低剂量和血药浓度监测来降低风险。

{"title":"Safety of Valproic Acid Use in Pregnant Women: A Systematic Review and Meta-Analysis","authors":"Xinying Yang, Yiqi Sun, Zixin Hua, Taoran Li, Xingang Li, Pengqiang Du","doi":"10.1111/jog.70121","DOIUrl":"https://doi.org/10.1111/jog.70121","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate valproic acid (VPA) safety in pregnancy versus other antiepileptic drugs (AEDs), focusing on fetal malformation risks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A literature search was conducted across PUBMED, MEDLINE, EMBASE, and Web of Science databases. Two researchers independently screened studies, extracted data, assessed quality, and analyzed VPA safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This meta-analysis of 25 safety studies showed that compared with other AEDs, VPA's teratogenic risks were as follows: combined major congenital malformations (RR = 2.36, 95% CI: 2.17–2.56), neural tube defects (RR = 6.54, 95% CI: 4.51–9.47), congenital heart defects (RR = 2.53, 95% CI: 2.16–2.96), cleft lip and/or palate (RR = 4.31, 95% CI: 3.06–6.08), genitourinary anomalies (RR = 3.32, 95% CI: 2.67–4.14), and musculoskeletal anomalies (RR = 2.88, 95% CI: 1.98–4.19). Additional analyses stratified by calendar era yielded consistent results, with the corresponding RR values for the above malformations being 2.43 (95% CI: 2.13–2.77), 6.64 (95% CI: 4.50–9.79), 2.64 (95% CI: 2.14–3.26), 4.27 (95% CI: 2.98–6.12), 3.45 (95% CI: 2.76–4.31), and 2.99 (95% CI: 2.00–4.46), indicating a higher risk of multiple malformations with VPA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>VPA monotherapy significantly increases teratogenic risk, especially for neural tube defects and cleft lip/palate. Newer AEDs with lower risk profiles are preferred for epilepsy treatment during pregnancy. If VPA use is unavoidable, low doses and blood concentration monitoring are recommended to mitigate risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Systemic Inflammatory Indices (NLR, PLR, SII) in Predicting the Response to Medical Treatment in Patients With Tubo-Ovarian Abscess: A Retrospective Evaluation 系统性炎症指数（NLR， PLR， SII）在预测输卵管卵巢脓肿患者药物治疗反应中的作用：一项回顾性评估

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-29 DOI: 10.1111/jog.70128

Mehmet Emre Peker, Ufuk Atlıhan, Duygu Uçar Kartal, Can Ata, Murat Özşahin

Objective

This study aimed to evaluate the role of systemic inflammatory indices—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)—in predicting the response to medical treatment in patients diagnosed with tubo-ovarian abscess (TOA).

Methods

This retrospective cross-sectional study included 100 female patients aged ≥ 18 years diagnosed with TOA between January 2020 and April 2025 at İzmir Buca Seyfi Demirsoy Training and Research Hospital and Manisa City Hospital. Patients were divided into two groups: those who responded to medical treatment (n = 50) and those who required surgical intervention after treatment failure (n = 50). Demographic, clinical, laboratory (NLR, PLR, SII, CRP), and radiological data (abscess diameter) were analyzed. Statistical analyses were conducted using SPSS version 27.0, with p < 0.05 considered significant.

Results

There were no significant differences between the groups regarding NLR (4.92 ± 2.80 vs. 4.87 ± 4.53; p = 0.947), PLR (163.7 ± 93.2 vs. 160.5 ± 139.2; p = 0.893), and SII (1570 ± 1096 vs. 1657 ± 1647; p = 0.756). However, CRP levels (89.8 ± 51.1 vs. 125.9 ± 67.1; p = 0.003) and abscess diameter (41.4 ± 19.1 mm vs. 68.9 ± 18.7 mm; p < 0.001) were significantly higher in the surgical group.

Conclusion

NLR, PLR, and SII showed limited value in predicting treatment response in TOA patients. Elevated CRP levels and larger abscess diameter were significant predictors of surgical need. Considering these factors may guide more individualized treatment strategies.

目的探讨中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）和全身免疫炎症指数（SII）在预测输卵管卵巢脓肿（TOA）患者药物治疗反应中的作用。方法回顾性横断面研究纳入İzmir Buca Seyfi Demirsoy培训和研究医院和马尼萨市医院2020年1月至2025年4月诊断为TOA的100例年龄≥18岁的女性患者。患者被分为两组：对药物治疗有反应的患者（n = 50）和治疗失败后需要手术干预的患者（n = 50）。分析了人口统计学、临床、实验室（NLR、PLR、SII、CRP）和放射学资料（脓肿直径）。采用SPSS 27.0版本进行统计学分析，p <； 0.05为显著性差异。结果NLR（4.92±2.80比4.87±4.53,p = 0.947）、PLR（163.7±93.2比160.5±139.2,p = 0.893）、SII（1570±1096比1657±1647，p = 0.756）组间差异无统计学意义。然而，CRP水平（89.8±51.1比125.9±67.1;p = 0.003）和脓肿直径（41.4±19.1 mm比68.9±18.7 mm; p < 0.001）明显高于手术组。结论NLR、PLR和SII在预测TOA患者治疗反应方面价值有限。CRP水平升高和脓肿直径增大是手术需求的重要预测因素。考虑这些因素可以指导更个性化的治疗策略。

{"title":"The Role of Systemic Inflammatory Indices (NLR, PLR, SII) in Predicting the Response to Medical Treatment in Patients With Tubo-Ovarian Abscess: A Retrospective Evaluation","authors":"Mehmet Emre Peker, Ufuk Atlıhan, Duygu Uçar Kartal, Can Ata, Murat Özşahin","doi":"10.1111/jog.70128","DOIUrl":"https://doi.org/10.1111/jog.70128","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate the role of systemic inflammatory indices—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)—in predicting the response to medical treatment in patients diagnosed with tubo-ovarian abscess (TOA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cross-sectional study included 100 female patients aged ≥ 18 years diagnosed with TOA between January 2020 and April 2025 at İzmir Buca Seyfi Demirsoy Training and Research Hospital and Manisa City Hospital. Patients were divided into two groups: those who responded to medical treatment (<i>n</i> = 50) and those who required surgical intervention after treatment failure (<i>n</i> = 50). Demographic, clinical, laboratory (NLR, PLR, SII, CRP), and radiological data (abscess diameter) were analyzed. Statistical analyses were conducted using SPSS version 27.0, with <i>p</i> < 0.05 considered significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were no significant differences between the groups regarding NLR (4.92 ± 2.80 vs. 4.87 ± 4.53; <i>p</i> = 0.947), PLR (163.7 ± 93.2 vs. 160.5 ± 139.2; <i>p</i> = 0.893), and SII (1570 ± 1096 vs. 1657 ± 1647; <i>p</i> = 0.756). However, CRP levels (89.8 ± 51.1 vs. 125.9 ± 67.1; <i>p</i> = 0.003) and abscess diameter (41.4 ± 19.1 mm vs. 68.9 ± 18.7 mm; <i>p</i> < 0.001) were significantly higher in the surgical group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>NLR, PLR, and SII showed limited value in predicting treatment response in TOA patients. Elevated CRP levels and larger abscess diameter were significant predictors of surgical need. Considering these factors may guide more individualized treatment strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 11","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer C1orf106在低级别浆液性卵巢癌中的表达及临床意义

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research

Pub Date : 2025-10-23 DOI: 10.1111/jog.70118

Feifei Song, Xiaojing Chen, Tao Zhang, Xuedong Tang, Xiaodong Cheng

Aim

Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer with distinct biological behavior. This study aimed to identify new biomarkers with potential diagnostic and prognostic value for LGSOC.

Methods

Gene-expression data were downloaded from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using R. Functional enrichment analyses were conducted to determine the biological functions and signaling pathways associated with DEGs. The mitogen-activated protein kinase (MAPK) pathway-related gene, chromosome 1 open reading frame 106 (C1orf106), was selected as the target gene. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to verify its expression. Associations between C1orf106 expression and the clinical features of patients were analyzed using the chi-square (χ²) test. Prognostic significance was evaluated with survival analyses.

Results

A total of 3099 upregulated and 4968 downregulated genes were identified in LGSOC. Gene set enrichment analysis (GSEA) demonstrated significant alterations in KRAS signaling and metabolic pathways between LGSOC and healthy controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed enrichment in immune response and MAPK pathway alterations. Immunohistochemistry and qRT-PCR confirmed that C1orf106 expression in LGSOC tissues was significantly higher than in normal ovarian tissues. Clinically, high C1orf106 expression was associated with lower BMI (< 25 kg/m²), the absence of visible residual disease, and improved progression-free survival (PFS) and overall survival (OS) in univariate Cox and Kaplan–Meier analyses.

Conclusions

C1orf106 may serve as a promising marker for the diagnosis and prognosis of LGSOC.

目的：低级别浆液性卵巢癌（LGSOC）是一种罕见的卵巢癌亚型，具有独特的生物学行为。本研究旨在寻找对LGSOC具有潜在诊断和预后价值的新生物标志物。方法：从Gene Expression Omnibus （GEO）下载基因表达数据。差异表达基因（differential expressed genes, deg）通过功能富集分析确定了与deg相关的生物学功能和信号通路。选择丝裂原活化蛋白激酶（MAPK）通路相关基因1号染色体开放阅读框106 （C1orf106）作为靶基因。免疫组织化学和定量实时聚合酶链反应（qRT-PCR）验证其表达。采用χ2检验分析C1orf106表达与患者临床特征的相关性。通过生存分析评估预后意义。结果：在LGSOC中共鉴定出3099个上调基因和4968个下调基因。基因集富集分析（GSEA）表明，在LGSOC和健康对照之间，KRAS信号和代谢途径发生了显著变化。京都基因和基因组百科全书（KEGG）和基因本体（GO）分析显示免疫反应和MAPK通路改变富集。免疫组织化学和qRT-PCR证实，C1orf106在LGSOC组织中的表达明显高于正常卵巢组织。在临床上，在单变量Cox和Kaplan-Meier分析中，高C1orf106表达与较低的BMI(2)、没有可见的残留疾病、改善的无进展生存期（PFS）和总生存期（OS）相关。结论：C1orf106可作为LGSOC的诊断和预后指标。

{"title":"The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer","authors":"Feifei Song, Xiaojing Chen, Tao Zhang, Xuedong Tang, Xiaodong Cheng","doi":"10.1111/jog.70118","DOIUrl":"10.1111/jog.70118","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Low-grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer with distinct biological behavior. This study aimed to identify new biomarkers with potential diagnostic and prognostic value for LGSOC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Gene-expression data were downloaded from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using R. Functional enrichment analyses were conducted to determine the biological functions and signaling pathways associated with DEGs. The mitogen-activated protein kinase (MAPK) pathway-related gene, chromosome 1 open reading frame 106 (<i>C1orf106</i>), was selected as the target gene. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to verify its expression. Associations between <i>C1orf106</i> expression and the clinical features of patients were analyzed using the chi-square (<i>χ</i><sup>2</sup>) test. Prognostic significance was evaluated with survival analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3099 upregulated and 4968 downregulated genes were identified in LGSOC. Gene set enrichment analysis (GSEA) demonstrated significant alterations in KRAS signaling and metabolic pathways between LGSOC and healthy controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed enrichment in immune response and MAPK pathway alterations. Immunohistochemistry and qRT-PCR confirmed that <i>C1orf106</i> expression in LGSOC tissues was significantly higher than in normal ovarian tissues. Clinically, high <i>C1orf106</i> expression was associated with lower BMI (< 25 kg/m<sup>2</sup>), the absence of visible residual disease, and improved progression-free survival (PFS) and overall survival (OS) in univariate Cox and Kaplan–Meier analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>C1orf106</i> may serve as a promising marker for the diagnosis and prognosis of LGSOC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/jog.70118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0